Elevation Oncology discontinues EO-3021 development due to insufficient efficacy in phase 1 trial, despite favorable safety profile. EO-3021 trial showed a 22.2% objective response rate and 72.2% ...

Elevation Oncology (ELEV) announced that it has elected to discontinue development of EO-3021. EO-3021 is a Claudin 18.2 antibody-drug ...

EO-3021 is a Claudin 18.2 antibody-drug conjugate (ADC), which Elevation Oncology was developing for the treatment of advanced, unresectable or metastatic gastric and gastroesophageal junction ...

EO-3021 is a Claudin 18.2 antibody-drug conjugate ... Elevation Oncology cannot guarantee future events, results, actions, levels of activity, performance or achievements, and the timing and ...

In the safety analysis of all enrolled patients (n=85), treatment with EO-3021 was observed to be generally well-tolerated, with an adverse event profile consistent with previously reported data ...